Nektar Therapeutics (NKTR) Free Cash Flow (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Free Cash Flow of -$44.3 million for Q1 2026, up 9.66% year-over-year from -$40.4 million in Q1 2025, and up 31.8% quarter-over-quarter from -$65.0 million in Q4 2025.
Nektar Therapeutics (NKTR) Free Cash Flow (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$44.3 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 9.66% year-over-year to -$44.3 million; the TTM figure through Mar 2026 stood at -$203.9 million (down 14.45% YoY), while the FY2025 annual figure was -$208.7 million, down 17.78% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$44.3 million, up from -$65.0 million in the prior quarter.
- The five-year high for Free Cash Flow was -$37.9 million in Q2 2024, with the low at -$92.6 million in Q1 2022.
- The 5-year median for Free Cash Flow is -$48.9 million (2025), against an average of -$54.9 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow surged 63.02% in 2022, then tumbled 39.3% in 2025.
- Nektar Therapeutics' Free Cash Flow stood at -$58.2 million in 2022, then climbed by 18.78% to -$47.3 million in 2023, then grew by 1.35% to -$46.6 million in 2024, then sank by 39.3% to -$65.0 million in 2025, then jumped by 31.8% to -$44.3 million in 2026.
- Business Quant data shows NKTR's Free Cash Flow at -$44.3 million in Q1 2026, -$65.0 million in Q4 2025, and -$48.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -44.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.32 Mn |
| Mar 31, 2026 | -44.32 Mn |
| Dec 31, 2025 | -64.98 Mn |
| Dec 31, 2025 | -64.98 Mn |
| Sep 30, 2025 | -48.88 Mn |
| Sep 30, 2025 | -48.88 Mn |
| Jun 30, 2025 | -45.78 Mn |
| Jun 30, 2025 | -45.78 Mn |
| Mar 31, 2025 | -49.06 Mn |
| Mar 31, 2025 | -49.06 Mn |
| Dec 31, 2024 | -46.65 Mn |
| Dec 31, 2024 | -46.65 Mn |
| Sep 30, 2024 | -44.60 Mn |
| Sep 30, 2024 | -44.60 Mn |
| Jun 30, 2024 | -37.89 Mn |
| Jun 30, 2024 | -37.89 Mn |
| Mar 31, 2024 | -48.05 Mn |
| Mar 31, 2024 | -48.05 Mn |
| Dec 31, 2023 | -47.28 Mn |
| Dec 31, 2023 | -47.28 Mn |